Daozhong W Zou

US Patent:

8124129, Feb 28, 2012

Filed:

Jul 12, 2006

Appl. No.:

11/988330

Inventors:

Russell Drew Cink - Grayslake IL, US
Daozhong Zou - Bridgewater NJ, US
Marvin Robert Leanna - Grayslake IL, US
Pascal H. Toma - Cary NC, US
Michelle Andrée Long - Libertyville IL, US

Assignee:

Karo Bio AB - Huddinge

International Classification:

A61K 9/14
A61K 31/56

US Classification:

424489, 514179, 514177, 514178

Abstract:

There is provided a hemihydrate of (3β,5β,7α,12α)-7,12-dihydroxy-3-{2-[{4-[17β-hydroxy-3-oxo-17α-prop-1-ynylestra-4,9-dien-11β-yl]phenyl}(methyl)amino]ethoxy}cholan-24-oic acid in a crystalline form which is characterised by an X-ray diffraction pattern having major peaks at 2θ=6. 580. 2, 8. 54+0. 2, 12. 280. 2, and 19. 680. 2. This crystalline material is useful in the treatment of conditions associated with an excess of hepatic glucocorticoid response.

US Patent:

20080064703, Mar 13, 2008

Filed:

Apr 26, 2007

Appl. No.:

11/789949

Inventors:

Eric Stoner - Kenosha WI, US
Alan Christesen - Round Lake IL, US
Ahmad Sheikh - Deerfield IL, US
Xiu Wang - Green Oaks IL, US
Agnes Pal - Grayslake IL, US
David Murphey - Gurnee IL, US
Jianguo Ji - Libertyville IL, US
Devalina Law - Libertyville IL, US
Daozhong Zou - Bridgewater NJ, US

International Classification:

A61K 31/501
A61P 25/34
C07D 401/14

US Classification:

514252040, 544238000

Abstract:

Compounds of formula (II): known as: 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1-H-indole salt with (2R, 3R)-2,3-dihydroxybutanedioic acid (1:1).

US Patent:

20230015251, Jan 19, 2023

Filed:

Aug 3, 2022

Appl. No.:

17/817163

Inventors:

- Basel, CH
Daozhong Zou - Raritan NJ, US

International Classification:

C07D 205/04
A61K 47/22
A61K 9/48
A61K 9/20
A61K 47/10

Abstract:

Provided herein are formulations, processes, solid forms and methods of use relating to (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid.

US Patent:

20210139420, May 13, 2021

Filed:

Jun 18, 2020

Appl. No.:

16/905441

Inventors:

- Basel, CH
Daozhong Zou - Raritan NJ, US

International Classification:

C07D 205/04
A61K 47/22
A61K 47/10
A61K 9/48
A61K 9/20

Abstract:

Provided herein are formulations, processes, solid forms and methods of use relating to (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid.

US Patent:

20200399213, Dec 24, 2020

Filed:

Jan 24, 2020

Appl. No.:

16/752041

Inventors:

- Basel, CH
Daozhong Zou - Raritan NJ, US

International Classification:

C07D 205/04
A61K 9/48
A61K 9/20

Abstract:

Provided herein are formulations, processes, solid forms and methods of use relating to (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid.

US Patent:

20200377454, Dec 3, 2020

Filed:

Aug 18, 2020

Appl. No.:

16/996720

Inventors:

- Basel, CH
Daozhong Zou - Raritan NJ, US

International Classification:

C07D 205/04
A61P 21/00
A61P 25/00
A61P 17/06

Abstract:

Provided herein are formulations, processes, solid forms and methods of use relating to (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid.

US Patent:

20190031619, Jan 31, 2019

Filed:

Oct 2, 2018

Appl. No.:

16/149393

Inventors:

- San Diego CA, US
Indrajit GHOSH - Hillsborough NJ, US
Lianfeng HUANG - Basking Ridge NJ, US
Daozhong ZOU - Raritan NJ, US

International Classification:

C07D 239/48

Abstract:

Provided are pharmaceutical compositions and dosage forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof. Also provided are methods of treating, managing, or preventing various disorders, such as diseases or disorders treatable or preventable by inhibition of a JNK pathway in mammals using such pharmaceutical compositions or dosage forms. Further provided are salts of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide and methods of preparation of such salts.

US Patent:

20180362498, Dec 20, 2018

Filed:

Jun 14, 2018

Appl. No.:

16/009080

Inventors:

- Pembroke, BM
Lianfeng Huang - Basking Ridge NJ, US
Ying Li - Millburn NJ, US
John Traverse - Lebanon NJ, US
Jean Xu - Warren NJ, US
Kelvin Hin-Yeong Yong - Westfield NJ, US
Daozhong Zou - Raritan NJ, US

International Classification:

C07D 401/12
A61K 31/506
C07D 403/12

Abstract:

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of one or both of ERK1 and ERK2.